We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Factors Driving Edwards Lifesciences to a New 52-Week High
Read MoreHide Full Article
Shares of Edwards Lifesciences Corporation (EW - Free Report) scaled a new 52-week high of $138.82 on Mar 8, closing the session lower at $138.25. The company has outperformed the industry over the last three months. The stock has gained 16.9%, compared with the S&P 500’s 3% gain and the industry’s 9.2%.
The stock has a market cap of $29.04 billion. The company has a positive earnings surprise of 9.9% for the last four quarters. Also, it has a long-term expected earnings growth rate of 15.1%.
Further, the company’s estimate revision trend for the current year is favorable. In the past couple of months, 11 analysts moved north, with no movement in the opposite direction. Earnings estimates rose around 8.2% to $4.49 per share.
The company’s five-year historical growth rate is also favorable at 23.4% as compared with the industry’s 10.6% and the S&P 500’s 2.8%.
Edwards Lifesciences carries a Zacks Rank #2 (Buy). The company has an impressive Growth Style Score of B as well. Our Growth Style Score highlights all the vital metrics of a company’s financials to obtain a clearer picture of the quality and sustainability of its growth. Our research shows that stocks with Style Scores of A or B when combined with a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold) offer the best investment opportunities.
Taking the stable stock performance into consideration, we expect Edwards Lifesciences to scale higher in the coming quarters based on several growth drivers:
Strong Fourth-Quarter Performance:
Edwards Lifesciences’ fourth-quarter 2017 performance was quite promising with revenues and earnings beating the Zacks Consensus Estimate. We are also encouraged by the strong performance by all three of the company’s product lines. The company also performed well with respect to gross and adjusted operating margin. The company is focusing on product innovation through research and development.
Solid Guidance:
Edwards Lifesciences has raised its 2018 sales expectations to the high end of the previously projected range of $3.5-$3.9 billion. The Zacks Consensus Estimate for full-year revenues is $3.71 billion, well within the guided range. Adjusted earnings per share expectation has also been raised to $4.43-$4.63 from the previous $4.10-$4.30. The Zacks Consensus Estimate for full-year adjusted earnings stands at $4.16, near the low end of the company’s guided range.
CE Mark for CENTERA Valve:
The market is upbeat about Edwards Lifesciences’ recent CE Mark for its self-expanding CENTERA valve. The regulatory approval is likely to boost the company's Transcatheter Heart Valves segment.
Acquisition of Harpoon Medical:
Edwards Lifesciences recently acquired Harpoon Medical, Inc. — a privately-held medical technology company focused on beating-heart repair for degenerative mitral regurgitation. Per the agreement, Harpoon Medical’s flagship beating-heart repair procedure for mitral valve patients — HARPOON system — will be added to Edward Lifesciences’ Surgical Heart Valve Therapy portfolio for treating structural heart diseases.
Other Key Picks
Other top-ranked stocks in the broader medical sector are PerkinElmer , Bio-Rad Laboratories (BIO - Free Report) and athenahealth, Inc. .
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Don’t Even Think About Buying Bitcoin Until You Read This
The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.
Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Bigstock
4 Factors Driving Edwards Lifesciences to a New 52-Week High
Shares of Edwards Lifesciences Corporation (EW - Free Report) scaled a new 52-week high of $138.82 on Mar 8, closing the session lower at $138.25. The company has outperformed the industry over the last three months. The stock has gained 16.9%, compared with the S&P 500’s 3% gain and the industry’s 9.2%.
The stock has a market cap of $29.04 billion. The company has a positive earnings surprise of 9.9% for the last four quarters. Also, it has a long-term expected earnings growth rate of 15.1%.
Further, the company’s estimate revision trend for the current year is favorable. In the past couple of months, 11 analysts moved north, with no movement in the opposite direction. Earnings estimates rose around 8.2% to $4.49 per share.
The company’s five-year historical growth rate is also favorable at 23.4% as compared with the industry’s 10.6% and the S&P 500’s 2.8%.
Edwards Lifesciences carries a Zacks Rank #2 (Buy). The company has an impressive Growth Style Score of B as well. Our Growth Style Score highlights all the vital metrics of a company’s financials to obtain a clearer picture of the quality and sustainability of its growth. Our research shows that stocks with Style Scores of A or B when combined with a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold) offer the best investment opportunities.
Taking the stable stock performance into consideration, we expect Edwards Lifesciences to scale higher in the coming quarters based on several growth drivers:
Strong Fourth-Quarter Performance:
Edwards Lifesciences’ fourth-quarter 2017 performance was quite promising with revenues and earnings beating the Zacks Consensus Estimate. We are also encouraged by the strong performance by all three of the company’s product lines. The company also performed well with respect to gross and adjusted operating margin. The company is focusing on product innovation through research and development.
Solid Guidance:
Edwards Lifesciences has raised its 2018 sales expectations to the high end of the previously projected range of $3.5-$3.9 billion. The Zacks Consensus Estimate for full-year revenues is $3.71 billion, well within the guided range. Adjusted earnings per share expectation has also been raised to $4.43-$4.63 from the previous $4.10-$4.30. The Zacks Consensus Estimate for full-year adjusted earnings stands at $4.16, near the low end of the company’s guided range.
CE Mark for CENTERA Valve:
The market is upbeat about Edwards Lifesciences’ recent CE Mark for its self-expanding CENTERA valve. The regulatory approval is likely to boost the company's Transcatheter Heart Valves segment.
Acquisition of Harpoon Medical:
Edwards Lifesciences recently acquired Harpoon Medical, Inc. — a privately-held medical technology company focused on beating-heart repair for degenerative mitral regurgitation. Per the agreement, Harpoon Medical’s flagship beating-heart repair procedure for mitral valve patients — HARPOON system — will be added to Edward Lifesciences’ Surgical Heart Valve Therapy portfolio for treating structural heart diseases.
Other Key Picks
Other top-ranked stocks in the broader medical sector are PerkinElmer , Bio-Rad Laboratories (BIO - Free Report) and athenahealth, Inc. .
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.
Bio-Rad Laboratories sports a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Don’t Even Think About Buying Bitcoin Until You Read This
The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.
Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 4 crypto-related stocks now >>